Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation

<div>Injection site–related treatment-emergent adverse events during the double-blind phase. <i>Note</i>. PP3M, paliperidone palmitate once-every-3-months; PP6M, paliperidone palmitate once-every-6-months; TEAE, treatment-emergent adverse event.</div>

Perspectives in Psychiatric Care

fig4

Figure 4

Figure 4: Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation 

Figure 4 | Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation 